Scott Liebman Dominick Disabatino

September 12, 2024 | New York Law Journal

Sheppard Mullen attorneys discuss 'Loper Bright Enterprises v. Raimondo and include the considerations stemming from the decision, both generally and with respect to FDA practice, specifically. They write: "Now, after having spent the summer pouring over cases, articles, and thought leadership on the matter, we're not sure the win is so sweeping—especially in the U.S. Food & Drug Administration arena."

By Scott Liebman, Dominick DiSabatino and Audrey Mercer

8 minute read